Table 2.
Best response among patients treated with weekly paclitaxel.
| Arm | Best Response | Median Follow-Up | Expired? | Prior weekly Paclitaxel + Carboplatin | Prior weekly Paclitaxel + Bevacizumab | Prior Weekly Paclitaxel |
|---|---|---|---|---|---|---|
| IXA | Not Assessed | 0.89 | Yes | Yes | ||
| IXA | Progressive Disease | 2.63 | Yes | Yes | ||
| IXA | Progressive Disease | 2.83 | Yes | Yes | ||
| IXA | Progressive Disease | 5 | Yes | Yes | ||
| IXA | Progressive Disease | 18.31 | Yes | Yes | ||
| IXA | Progressive Disease | 24.79 | Yes | Yes | ||
| IXA | Stable Disease | 1.94 | Yes | Yes | ||
| IXA | Stable Disease | 2.1 | Yes | Yes | ||
| IXA | Stable Disease | 5 | Yes | Yes | ||
| IXA | Stable Disease | 6.41 | Yes | Yes | ||
| IXA | Stable Disease | 12.2 | Yes | Yes | ||
| IXA | Stable Disease | 33.6 | Yes | Yes | ||
| IXA | Stable Disease | 67.36 | No | Yes | ||
| IXA+BEV | Progressive Disease | 5.23 | Yes | Yes | ||
| IXA+BEV | Stable Disease | 2.17 | Yes | Yes | ||
| IXA+BEV | Stable Disease | 6.44 | Yes | Yes | ||
| IXA+BEV | Stable Disease | 7.92 | Yes | Yes | ||
| IXA+BEV | Stable Disease | 20.15 | Yes | Yes | ||
| IXA+BEV | Stable Disease | 40.11 | Yes | Yes | ||
| IXA+BEV | Stable Disease | 61.71 | No | Yes | Yes | |
| IXA+BEV | Partial Response | 18.61 | Yes | Yes | ||
| IXA+BEV | Partial Response | 31.59 | No | Yes | ||
| IXA+BEV | Partial Response | 38.24 | No | Yes |